LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN ADENOMYOSIS; PREDICTORS FOR RESPONSE AND CLINICAL OUTCOME
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.27109Keywords:
Adenomyosis, Levonorgestrel-releasing intrauterine system, Uterine volumeAbstract
Objectives: The aim is to detect clinical and ultrasonographic characters that predict the response of adenomyosis to levonorgestrel-releasing intrauterine system (LNG-IUS) and to evaluate the clinical efficacy and the time needed to show a response.
Methods: A prospective single-arm study conducted in the Obstetrics and Gynaecology Department Al-Yarmouk Teaching Hospital in Baghdad/Iraq from August 2015 to March 2018. Women with symptomatic adenomyosis with age 39 years and above and who completed their families had been enrolled in this study. LNG-IUS was used as a treatment; the outcome measure was to evaluate its effect in improving the symptoms and the time needed to show a clinical response. Multivariate analysis was used to assess the contribution of the clinical and ultrasonographic parameters to the prediction of the response to LNG-IUS.
Results: Over the mean duration of follow-up period of the study (22.7±9.9 months), there was a significant improvement in menstrual blood loss, dysmenorrhea, and hemoglobin (Hb) with significant decrease in uterine volume (p˂0.001). The time to show response was as early as 3 months and the first 6 months is the best time to predict failure. Initial menstrual blood loss and Hb were good predictors to show response while uterine volume an excellent one (positive predictive value 80% and negative predictive value 97.2%).
Conclusion: Levonorgestrel-releasing intrauterine device is an effective treatment of symptomatic adenomyosis in term of time to response and duration of response. The presenting Hb, menstrual blood loss, and uterine volume are useful predictors of response.
Downloads
References
Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:603-16.
Vercellini P, Viganò P, Somigliana E, Daguati R, Abbiati A, Fedele L, et al. Adenomyosis: Epidemiological factors. Best Pract Res Clin Obstet Gynaecol 2006;20:465-77.
Krentel H, Cezar C, Becker S, Di Spiezio Sardo A, Tanos V, Wallwiener M, et al. Review article from clinical symptoms to MR imaging: Diagnostic steps in adenomyosis. BioMed Res Int 2017;2017:6.
Brucker SY, Huebner M, Wallwiener M, Stewart EA, Ebersoll S, Schoenfisch B, et al. Clinical characteristics indicating adenomyosis coexisting with leiomyomas: A retrospective, questionnaire-based study. Fertil Steril 2014;101:237-410.
Yoo HJ, Lee MA, Ko YB, Yang JB, Kang BH, Lee KH, et al. The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea. Arch Gynecol Obstet 2012;285:161-6.
Dash S, Mishra J, Behera SS, Rout S. Therapeutic efficacy of levonorgestrel intrauterine system as an alternative to hysterectomy for management of heavy menstrual bleeding in perimenopausal women. Asian J Pharm Clin Res 2018;11:289-92.
Fedele L, Bianchi S, Frontino G. Hormonal treatments for adenomyosis. Best Pract Res Clin Obstetr Gynaecol 2008;22:333-9.
Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95:497-502.
Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception 2010;82:396-403.
Sabbioni L, Petraglia F, Luisi S. Non-contraceptive benefits of intrauterine levonorgestrel administration: Why not? Gynecol Endocrinol 2017;33:822-9.
Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-9.
Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E, et al. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 2001;16:2103-8.
Critchley HO, Wang H, Kelly RW, Gebbie AE, Glasier AF. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998;13:1210-7.
Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198:373, e1-7.
Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9.
Dixon JS, Bird HA. Reproducibility along a 10 cm vertical visual analogue scale. Ann Rheum Dis 1981;40:87-9.
Dartmouth K. A systematic review with meta-analysis: The common sonographic characteristics of adenomyosis. Ultrasound 2014;22:148-57.
Verit FF, Yucel O. Endometriosis, leiomyoma and adenomyosis: The risk of gynecologic malignancy. Asian Pac J Cancer Prev 2013;14:5589-97.
Venugopalan SK, Pandian NS, Pavani M, Rao TS, Rajini Y, Khadeer SK, et al. abnormal uterine bleeding in reproductive women: Diagnosis, management and treatment. Asian J Pharm Clin Res 2015;8:42-5.
Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update 2015;21:640-51.
Kelekci S, Kelekci KH, Yilmaz B. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. Contraception 2012;86:458-63.
Lee KH, Kim JK, Lee MA, Ko YB, Yang JB, Kang BH, et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis. Arch Gynecol Obstet 2016;294:561-6.
Merki-Feld GS, Schwarz D, Imthurn B, Keller PJ. Partial and complete expulsion of the multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion. Eur J Obstet Gynecol Reprod Biol 2008;137:92-6.
Socolov D, Blidaru I, Tamba B, Miron N, Boiculese L, Socolov R, et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care 2011;16:480-7.
Zhang P, Song K, Li L, Yukuwa K, Kong B. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis. Med Princ Pract 2013;22:480-3.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
